Poliomyelitis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Poliomyelitis – Pipeline Review, H1 2020’, provides an overview of the Poliomyelitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Poliomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Poliomyelitis

– The report reviews pipeline therapeutics for Poliomyelitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Poliomyelitis therapeutics and enlists all their major and minor projects

– The report assesses Poliomyelitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Poliomyelitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Poliomyelitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Poliomyelitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co Ltd

Beijing Tiantan Biological Products Co Ltd

Bharat Biotech Ltd

Biken Co Ltd

Biological E Ltd

Biological Mimetics Inc

Boryung Pharmaceutical Co Ltd

CanSino Biologics Inc

Cleveland BioLabs Inc

GlaxoSmithKline Plc

Grifols SA

Johnson & Johnson

KM Biologics Co Ltd

LG Chem Ltd

Micron Biomedical Inc

Nanolek LLC

Panacea Biotec Ltd

Sanofi Pasteur SA

Shantha Biotechnics Pvt Ltd

Univercells SA

Wuhan Institute of Biological Products Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Poliomyelitis - Overview

Poliomyelitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Poliomyelitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Poliomyelitis - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Beijing Tiantan Biological Products Co Ltd

Bharat Biotech Ltd

Biken Co Ltd

Biological E Ltd

Biological Mimetics Inc

Boryung Pharmaceutical Co Ltd

CanSino Biologics Inc

Cleveland BioLabs Inc

GlaxoSmithKline Plc

Grifols SA

Johnson & Johnson

KM Biologics Co Ltd

LG Chem Ltd

Micron Biomedical Inc

Nanolek LLC

Panacea Biotec Ltd

Sanofi Pasteur SA

Shantha Biotechnics Pvt Ltd

Univercells SA

Wuhan Institute of Biological Products Co Ltd

Poliomyelitis - Drug Profiles

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Poliomyelitis - Dormant Projects

Poliomyelitis - Discontinued Products

Poliomyelitis - Product Development Milestones

Featured News & Press Releases

Apr 23, 2020: AJ Vaccines secures WHO Prequalification for polio vaccine Picovax

Apr 16, 2019: Sinovac announces positive results from Phase III trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) published in the journal of Infectiou

Jan 11, 2019: Univercells introduces breakthrough vaccine manufacturing platform

May 21, 2018: A single-injection vaccine for the polio virus

Apr 19, 2018: Sinovac Announces Preliminary Results of Phase III Trial on sIPV

Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate

May 11, 2011: Sanofi Pasteur Launches Pentaxim In China

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Poliomyelitis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Poliomyelitis – Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020

Poliomyelitis – Pipeline by Beijing Tiantan Biological Products Co Ltd, H1 2020

Poliomyelitis – Pipeline by Bharat Biotech Ltd, H1 2020

Poliomyelitis – Pipeline by Biken Co Ltd, H1 2020

Poliomyelitis – Pipeline by Biological E Ltd, H1 2020

Poliomyelitis – Pipeline by Biological Mimetics Inc, H1 2020

Poliomyelitis – Pipeline by Boryung Pharmaceutical Co Ltd, H1 2020

Poliomyelitis – Pipeline by CanSino Biologics Inc, H1 2020

Poliomyelitis – Pipeline by Cleveland BioLabs Inc, H1 2020

Poliomyelitis – Pipeline by GlaxoSmithKline Plc, H1 2020

Poliomyelitis – Pipeline by Grifols SA, H1 2020

Poliomyelitis – Pipeline by Johnson & Johnson, H1 2020

Poliomyelitis – Pipeline by KM Biologics Co Ltd, H1 2020

Poliomyelitis – Pipeline by LG Chem Ltd, H1 2020

Poliomyelitis – Pipeline by Micron Biomedical Inc, H1 2020

Poliomyelitis – Pipeline by Nanolek LLC, H1 2020

Poliomyelitis – Pipeline by Panacea Biotec Ltd, H1 2020

Poliomyelitis – Pipeline by Sanofi Pasteur SA, H1 2020

Poliomyelitis – Pipeline by Shantha Biotechnics Pvt Ltd, H1 2020

Poliomyelitis – Pipeline by Univercells SA, H1 2020

Poliomyelitis – Pipeline by Wuhan Institute of Biological Products Co Ltd, H1 2020

Poliomyelitis – Dormant Projects, H1 2020

Poliomyelitis – Dormant Projects, H1 2020 (Contd..1), H1 2020

Poliomyelitis – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Poliomyelitis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports